STAT6 Modulator

Medrysone (HMS) is a glucocorticoid receptor modulator and a STAT6 pathway enhancer. Medrysone enhances cytokine-induced STAT6 phosphorylation, which is required for M2-type macrophage polarization, and promotes VEGF and CCL2 secretion, vascular endothelial cell migration, and corneal injury repair. Medrysone can be used in research on corneal injury and elevated intraocular pressure.

Pabgraminone C (IM502) is a Fungal metabolite and PI3Kγ inhibitor with an IC₅₀ of 61.7 nM against PI3Kγ. Pabgraminone C shifts the STAT signaling pathway in cells from an immunosuppressive STAT3/STAT6-dominant profile to an immunostimulatory STAT1/STAT2-dominant profile, driving cells toward a pro-inflammatory phenotype. Pabgraminone C reprograms cells from an immunosuppressive state to an immunostimulatory state, reversing their suppressive effect on anti-tumor immunity. Pabgraminone C inhibits established tumor growth and metastasis across multiple cancer types. Pabgraminone C overcomes resistance to PD-1 checkpoint blockade strategies. Pabgraminone C can be used in research related to liver cancer, melanoma, and colorectal cancer.

(trans)-STAT6-IN-13 (Compound 95) is a STAT6 inhibitor with IC₅₀ values of ≤300 nM. (trans)-STAT6-IN-13 has weak inhibitory for STAT3. (trans)-STAT6-IN-13 can be used for the researches of cancer, inflammation and immunology.

Medrysone (Standard) (HMS (Standard); 6α-Methyl-11β-hydroxyprogesterone (Standard)) is the analytical standard of Medrysone (HY-B1076). This product is intended for research and analytical applications. Medrysone (HMS) is a glucocorticoid receptor modulator and a STAT6 pathway enhancer. Medrysone enhances cytokine-induced STAT6 phosphorylation, which is required for M2-type macrophage polarization, and promotes VEGF and CCL2 secretion, vascular endothelial cell migration, and corneal injury repair. Medrysone can be used in research on corneal injury and elevated intraocular pressure.